Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8442012 | European Journal of Cancer | 2015 | 10 Pages |
Abstract
Single-agent panitumumab is active and well tolerated and may be a therapeutic option for high-risk frail elderly patients with WT RAS tumours considered not candidates for chemotherapy (clinicaltrials.gov identifier NCT01126112).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
J. Sastre, B. Massuti, G. Pulido, C. Guillén-Ponce, M. Benavides, J.L. Manzano, M. Reboredo, F. Rivera, C. Grávalos, M.J. Safont, M. MartÃnez Villacampa, P. Llovet, E. Dotor, E. DÃaz-Rubio, E. Aranda,